Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics, Inc. is the subject of a Schedule 13G/A disclosing institutional holdings in its common stock. Janus Henderson Group plc reports beneficial ownership of 4,102,620 shares, representing 10.6% of the class, with shared voting and dispositive power over those shares. A related vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports beneficial ownership of 3,512,932 shares, or 9.1%. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure includes a power of attorney authorizing certain compliance officers to file required reports.
Protara Therapeutics, Inc. filed a Form S-8 to register an additional 2,800,000 shares of common stock for issuance under its 2024 Equity Incentive Plan, following a board amendment adopted on April 17, 2025 and stockholder approval at the annual meeting on June 11, 2025. The filing incorporates by reference the company’s prior Form S-8 (filed August 6, 2024) and specified SEC reports, including the Annual Report filed March 5, 2025 and Quarterly Reports filed May 8, 2025 and August 11, 2025.
The registration statement discloses corporate governance items such as indemnification provisions and the inclusion of a DGCL 102(b)(7) limitation on director liability in the certificate of incorporation, and indicates the company is a non-accelerated filer and a smaller reporting company.
Protara Therapeutics is a clinical-stage biopharmaceutical company advancing TARA-002 (cell therapy) and IV Choline Chloride (intravenous choline) and has no product revenues. For the six months ended June 30, 2025 the company reported a net loss of $26.9 million versus $20.6 million in the prior year period, driven by higher research and development and general and administrative expenses. Cash and cash equivalents declined to $31.5 million while marketable debt securities increased after purchases, leaving $145.6 million in unrestricted cash and marketable securities and $115.3 million in working capital, which management states is sufficient for at least twelve months.
The company highlighted clinical progress: interim ADVANCED-2 data showed high complete response rates in small cohorts (BCG-Unresponsive 100% any-time CR 5/5; BCG-Naive 76% any-time CR 16/21) with mostly Grade 1 adverse events and no Grade 3+ treatment-related events. IV Choline Chloride received FDA Fast Track and orphan considerations and patents through 2041; Protara plans to initiate the THRIVE-3 registrational trial in Q3 2025 and obtained EU-CTR approval in July 2025. Recent financings include a December 2024 public offering (gross ~$100.1M, net ~$93.4M) and an April 2024 private placement (net ~$41.96M). The company notes it will need additional capital to fully execute its clinical plans.
On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.